CoronaryAtlas logo
CoronaryAtlas
Interleukin-17E
Pathway / Plaque inflammation

Interleukin-17E

IL17Fprotein

IL-17E drives vascular inflammation and predicts post-MI cardiac remodeling through pro-inflammatory T-cell signaling.

Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleInflammatory mediator in CAD; IL-17 family promotes plaque inflammation and destabilization.
Also acts inPlatelet activation
Druggability
DruggableYes
Known drugs / candidates2
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000112116

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
26
C — confounder / Type-II
49
A — assay feasibility
72
E — evidence strength
19
T1DI (composite)
5
Specificity differential (R−C)-22.8
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(3)